Breaking News
0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Axonics (AXNX) Upbeat On Results Of Its ARTISAN-SNM Study

By Zacks Investment ResearchStock MarketsOct 07, 2019 10:05PM ET
www.investing.com/analysis/axonics-axnx-upbeat-on-results-of-its-artisansnm-study-200471549
Axonics (AXNX) Upbeat On Results Of Its ARTISAN-SNM Study
By Zacks Investment Research   |  Oct 07, 2019 10:05PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 

Axonics Modulation Technologies, Inc. (NASDAQ:AXNX) has presented a favorable outcome of its detailed one-year ARTISAN-SNM pivotal study at the joint scientific meeting of the American Urogynecologic Society (AUGS) and the International Urogynecological Association (IUGA). This came on the heels of the FDA approval of the Axonics r-SNM System1 in September 2019.

In the session, it showcased the Axonics r-SNM System and received first-hand impressions of various medical practitioners that attended. The company also received feedback on post-implant patients from physician implanters who took part in the study.

With the positive study results, the company aims to strengthen foothold in the implantable Sacral Neuromodulation (“SNM”) devices market.

Few Words on SNM

Approximately, 87 million adults in the United States and Europe suffer from urinary and bowel dysfunction. Another estimated 40 million adults reportedly suffer from fecal incontinence/accidental bowel leakage.

SNM therapy takes care of the problem by reducing and restoring pelvic floor function.

A Closer Look at the Study

The presentation (titled ‘Treatment of urinary urgency incontinence with the Axonics miniaturized, rechargeable SNM system: Clinical outcomes of the ARTISAN-SNM pivotal study’) shows results of the clinical study over 12 months. It highlights the important advancements observed in patients with respect to urinary urgency incontinence symptoms and quality of life after implanted with Axonics r-SNM System.

The study of ARTISAN-SNM is approved under the FDA Investigational Device Exemption to assess the safety and efficiency of the Axonics r-SNM System for urinary dysfunction.

Why is the Study a Breakthrough?

The study results were quite impressive as it proved that there were no serious device-related negative impacts after the implants. Also, there was a significant improvement in urgency incontinence episodes in most of the patients, contrary to earlier treatment options.

Industry Prospects

Per a report by Reports And Data, the global SNM market was valued at $2189.1 million in 2018 and is expected to reach $3153.4 million by 2026, seeing a CAGR of 4.94%. Key factors driving the market are the rising demand for minimally invasive therapy, increasing incidents of urinary bladder diseases and various technological advancements.

Recent Developments

Axonics signed an agreement with Adult Pediatric Urology and Urogynecology (“ADPU”) in October 2019 to supply its product, Axonics r-SNM System. ADPU is a pioneer in the SNM treatment of urinary and bowel dysfunction, and its physicians have been successful in implanting SNM devices for quite a long time. Axonics received the FDA clearance for the product in September 2019.

In June 2019, the company received the FDA nod for the use of full-body MRI, using 1.5 Tesla (NASDAQ:TSLA) MRI scanners for patients implanted with the Axonics System as part of its clinical study.

Comparison With Peers

In the SNM care space, a number of bigwigs are actively looking to tap bountiful opportunities. Medtronic plc (NYSE:MDT) recently received the FDA approval for the InterStim(TM) smart programmer to be used with the InterStim system.

Abbott Laboratories (NYSE:ABT) announced results of a new study, which confirmed that higher levels of a protein measured, with Abbott's blood test under development, could help detect mild traumatic brain injuries (“TBI”s), even when a CT scan failed to detect it.

Nuvectra Corporation (NASDAQ:NVTR) has announced that its Virtis SNM system is currently under the FDA review. The company is closely working with the FDA to complete its pre-market approval (PMA) application for the Virtis platform.

Wall Street’s Next Amazon (NASDAQ:AMZN)

Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.

Click for details >>



Abbott Laboratories (ABT): Free Stock Analysis Report

Nuvectra Corporation (NVTR): Free Stock Analysis Report

Medtronic PLC (MDT): Free Stock Analysis Report

Axonics Modulation Technologies, Inc. (AXNX): Free Stock Analysis Report

Original post

Zacks Investment Research
Axonics (AXNX) Upbeat On Results Of Its ARTISAN-SNM Study
 

Related Articles

Axonics (AXNX) Upbeat On Results Of Its ARTISAN-SNM Study

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email